Navigation Links
Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
Date:3/15/2012

NEW YORK, March 15, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT® Delivery System with the Institut Gustave Roussy ("IGR"), a leading European cancer center located in Villejuif, France. Under the terms of the agreement, the Company will provide the IGR with logistics and clinical training support in chemosaturation therapy using the CHEMOSAT system. The Company expects training at the IGR to begin in April 2012. Upon completion of training, the IGR will be the first cancer center to commercially utilize the CHEMOSAT system to treat patients in France.

Thierry de Baere, Director of the Department of Interventional Radiology at the Institut Gustave Roussy, added, "Research suggests that CHEMOSAT will offer us a clinically meaningful tool against cancers in the liver. We look forward to working with the Delcath team to explore the product's potential."

"This agreement obviously builds on our recent momentum in establishing initial training centers to begin the launch of CHEMOSAT in Europe, and we're pleased to be working with such a prestigious institution as the IGR to introduce the product into France," said Eamonn P. Hobbs, President and CEO of Delcath System.

About the Institut Gustave RoussyThe Institut Gustave Roussy ("IGR") is a nonprofit academic entity with global expertise in the mission to fight cancer. Based in Villejuif, France, the IGR is a wholly patient-oriented leading European Comprehensive Cancer Center belonging to the French public hospital service. Created in 1921 by the then rector of the Academy of Paris, Gustave Roussy, the IGR was joined in 1925 by the Regional Centre for the fight against cancer in the Paris suburbs. Located south of Paris on a single site, IGR employs 2
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/hxhwtv/asia_pacific ) has announced ... - Growth, Trends And Forecasts (2014 - 2019)" ... Asia Pacific market for Fluoroscopy is ... to 2020 Fluoroscopy is the imaging technology ... the interior of the body. The imaging team consists ...
(Date:5/27/2015)... May 27, 2015 ... du décalage horaire. Il nuit sérieusement à ... concentration durant les réunions de mi-journée et ... au mauvais moment dans votre chambre d,hôtel. ... décalage horaire risque de vous empêcher de ...
(Date:5/27/2015)... Donatelli, a senior marketing associate with the animal health division of Eli ... a healthcare setting in Bangkok, Thailand , will be ... need with respect and dignity is the guiding star for me and ... in a LillyPad blog . Donatelli and Lilly colleagues ... Colombia , France , Ukraine ...
Breaking Medicine Technology:Asia Pacific Fluoroscopy Market Trends and Forecasts 2014 - 2019 2HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 2HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 4Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3
... Decas SDCs Offer Greater Amounts of the Natural Compound Responsible ... Antioxidant and Anti-adhesion ... Inc.,announced today the results of new research showing that 1 ... has twice the,proanthocyanidin (PAC) level of an 8-ounce glass of ...
... MATEO, Calif., Dec. 12 BioForm Medical,Inc. (Nasdaq: ... a multi-center,randomized, blinded comparative study of nasolabial fold ... filler,than reported after treatment with either Juvederm(TM) or ... the December 2007 Filler Issue of,the Journal of ...
Cached Medicine Technology:Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail 2Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 2Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 3Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 4Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 5Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 6
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 ... the current state of the Omega-3 industry. The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ... Gc Rieber Oils, Camanchaca Fishing Company, Seadragon Marine ...
(Date:5/27/2015)... May 27, 2015 SonarMD, ... SonarMD Platform, a first-of-its kind, cloud-based algorithmic ... patients with chronic gastrointestinal disease. , Developed ... the application allows physicians to monitor their ... ongoing use of electronic health assessment surveys. ...
(Date:5/27/2015)... “Heroin has never been more plentiful or cheaper, ... from,” says Harford County Sheriff Jeff Gahler, as quoted by ... surging heroin related incidents in Baltimore, police resources are running ... heroin addiction and subsequent abuse before it turns into a ... is a drug and alcohol rehab facility specializing in heroin ...
(Date:5/27/2015)... Fernando Valley, CA (PRWEB) May 27, 2015 ... , Dr. Peyman Ghasri, is now offering discounts on facial ... every year after the age of 18. This lost collagen ... eyes, sunken cheeks, wrinkles and expression lines. Facial fillers are ... volume. Many people turn to facial fillers to create a ...
(Date:5/27/2015)... 27, 2015 A television program using ... and Roswell Park Cancer Institute winning ... award-winning story, Cancer Can’t Win , highlights the ... Cancer Institute. The production team followed five people who ... as they received treatment from doctors and medical experts ...
Breaking Medicine News(10 mins):Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Discounts on Facial Fillers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 3
... Southwestern Medical Center have determined that the level, or saturation, ... with sickle cell anemia who are at an increased risk ... also found that a published method used to predict severe ... Stroke is a serious but increasingly preventable complication of sickle ...
... cash flow from operations achieved for Q4 and the ... AMCS ),a leader in radiology and medical image ... the fourth,quarter and year ended December 31, 2007., ... Q4 Financial Highlights Revenue: Total revenues for ...
... Investigation into allergic reactions, deaths related to blood thinner ... Healthcare Corp., the pharmaceutical company at the center of ... that it was recalling any remaining multi-dose vials of ... company also said it was recalling its Hep-Lock heparin ...
... to Reliance on Spill-Proof,Cups, GLENDALE, Calif., Feb. 28 ... Dental Hygienists, Association,(CDHA) today urged parents and caregivers to ... "We all know that sippy cups are a godsend ... "But they need to be used wisely and,properly in ...
... The Board of Directors of,Belden (NYSE: BDC ... and member of,the Compensation Committee of the board. Ms. ... Resources at Pfizer Inc., a post she has held,since ... world,s largest global,research-based pharmaceutical company. Prior to joining Pfizer, ...
... Changes in standards support Department of Health ... improvement, WASHINGTON, Feb. 28 Today ... its Core Accreditation standards. The Core,standards are ... functions within health care organization such as ...
Cached Medicine News:Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 2Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 3Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 4Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 5Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 6Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 7Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 8Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 9Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 10Health News:AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007 11Health News:Baxter Recalls Rest of Heparin Products 2Health News:Baxter Recalls Rest of Heparin Products 3Health News:California Dental Hygienists Offer Tips for Safe Sippy Cup Use 2Health News:Belden Appoints Mary S. McLeod of Pfizer Inc. to Board of Directors 2Health News:URAC Invites Health Management Industry, Public for Comments on Changes to Its Core Accreditation Standards 2Health News:URAC Invites Health Management Industry, Public for Comments on Changes to Its Core Accreditation Standards 3
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Inquire...
Medicine Products: